Natixis Lowers Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)

Natixis lowered its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 98.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,170 shares of the company's stock after selling 83,624 shares during the period. Natixis' holdings in Revolution Medicines were worth $51,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in RVMD. Vanguard Group Inc. raised its position in shares of Revolution Medicines by 14.7% during the 4th quarter. Vanguard Group Inc. now owns 17,096,455 shares of the company's stock valued at $747,799,000 after buying an additional 2,185,082 shares during the period. Lord Abbett & CO. LLC acquired a new position in shares of Revolution Medicines in the 3rd quarter valued at $83,082,000. Norges Bank purchased a new position in shares of Revolution Medicines during the 4th quarter worth $76,197,000. FMR LLC increased its position in shares of Revolution Medicines by 14.7% during the 4th quarter. FMR LLC now owns 6,742,083 shares of the company's stock worth $294,899,000 after purchasing an additional 866,190 shares during the last quarter. Finally, Pictet Asset Management Holding SA increased its position in shares of Revolution Medicines by 4,399.6% during the 4th quarter. Pictet Asset Management Holding SA now owns 712,596 shares of the company's stock worth $31,169,000 after purchasing an additional 696,759 shares during the last quarter. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RVMD has been the subject of several research analyst reports. Wedbush reaffirmed an "outperform" rating and set a $67.00 target price on shares of Revolution Medicines in a research note on Monday. UBS Group upped their price target on Revolution Medicines from $65.00 to $71.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. HC Wainwright raised their price target on Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Needham & Company LLC reissued a "buy" rating and set a $59.00 target price on shares of Revolution Medicines in a research note on Tuesday, April 8th. Finally, Stifel Nicolaus lowered their target price on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $66.67.

Insider Activity

In other news, COO Margaret A. Horn sold 3,058 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $119,384.32. Following the transaction, the chief operating officer now directly owns 153,533 shares in the company, valued at approximately $5,993,928.32. This trade represents a 1.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Mark A. Goldsmith sold 11,738 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $458,251.52. Following the sale, the insider now directly owns 441,564 shares of the company's stock, valued at approximately $17,238,658.56. This represents a 2.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,660 shares of company stock worth $650,406. 8.00% of the stock is currently owned by insiders.

Revolution Medicines Stock Up 7.0 %

Revolution Medicines stock traded up $2.70 during trading on Monday, reaching $41.47. The stock had a trading volume of 2,872,304 shares, compared to its average volume of 1,437,485. Revolution Medicines, Inc. has a 52-week low of $29.17 and a 52-week high of $62.40. The stock has a market cap of $7.71 billion, a PE ratio of -11.55 and a beta of 1.37. The business has a 50 day moving average price of $37.42 and a 200 day moving average price of $43.95.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($1.12) EPS for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.11). On average, equities analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.